-
BeyondSpring Granted Patent for Plinabulin
americanpharmaceuticalreview
May 18, 2020
BeyondSpring announced the United States Patent and Trademark Office (USPTO) has granted the Company a new patent.
-
Boehringer Ingelheim acquires Northern Biologics’ preclinical cancer antibody pipeline
expresspharma
May 18, 2020
The acquisition provides assets targeting tumour stroma and myeloid cells.
-
Attenuated Diptheria Toxin Developed by Researchers as Novel Form of Drug Delivery
Europeanpharmaceuticalreview
May 07, 2020
A new potential platform for drug delivery has been created by researchers using attentuate diptheria toxin, which can enter cells and escape the endosome.
-
DelMar Updates Clinical Trial of VAL-083 for Adjuvant Treatment of Brain Tumors
americanpharmaceuticalreview
May 07, 2020
DelMar Pharmaceuticals has enrolled 22 patients in the adjuvant arm of the Company's ongoing Phase 2 clinical study investigating adjuvant treatment (pre-temozolomide -- or TMZ -- maintenance therapy) of MGMT-unmethylated glioblastoma multiforme (GBM) ...
-
AGC Biologics Inks Manufacturing Deal with Faron
contractpharma
May 07, 2020
The CDMO will manufacture novel precision cancer immunotherapy treatment Clevegen.
-
Crescendo links with CRUK to progress cancer therapy
pharmatimes
May 06, 2020
Crescendo Biologics and Cancer Research UK have entered into a Clinical Development Partnership to progress one of Crescendo’s novel bispecific Humabody immunotherapies, CB213, into clinical trials targeting cancers of high unmet medical need.
-
Bayer faces second investor reckoning over glyphosate litigation
expresspharma
April 29, 2020
Criticism from investors at this year’s annual shareholders’ meeting – held in a virtual format with gatherings banned due to the coronavirus – will likely be less scathing than it was in 2019.
-
NICE backs NHS use of Bayer's Vitrakvi via the CDF
pharmatimes
April 26, 2020
Bayer's Vitrakvi (larotrectinib) will be available via the NHS in England and Wales to treat a variety of cancers.
-
Novel cannabinoid formula could be used as a cancer treatment
europeanpharmaceuticalreview
April 17, 2020
The developers of the novel formulation, containing the cannabinoids CBDV and CBGA, now intend to test the clinical safety and efficacy of its anti-cancer activity.
-
TScan and Novartis partner to develop cancer therapies
pharmaceutical-technology
April 17, 2020
Biopharmaceutical firm TScan Therapeutics has signed an agreement with Novartis to discover and develop therapies for the treatment of cancer.